Innogene Kalbiotech, a subsidiary of PT Kalbe Farma to penetrate global market

Not only does it wasn’t to be the best in the country but (at the moment "JSX: KLBF" have become the biggest Pharmaceutical company in the Jakarta Stock Exchange), T Kalbe Farma wishes to penetrate the global market, by inventing new products (internationally patented). Hence Indonesia can be proud of the original pharmaceutical drugs produced by PT Kalbe Farma. Through Innogene Kalbiotech, Kalbe Farma will become a drug development companywhich focuses on clinical development. Such is the resolution from the Press Conference held at PT Kalbe Farma’s Marketing Office on Friday, July 29th, 2005.

Innogene Kalbiotech
Innogene Kalbiotech which stands for Innovation Generator Kalbe Farma Biotechnology is a subsidiary of Pt Kalbe Farma, it started on July 8th, 2003. Based on superior science and technology, the company strive to be the best in Pharmaceutical business and invent top products which can penetrate the markets in developed countries. According to Dr Rikrik Ilyas, as Director of Innogene Kalbiotech, besides the drug developments, the company also creates innovative diagnostic equipment which requires scientific and clinical developments in Global Market. From the aspect of class therapy, Innogene specializes itself in the developments of Oncology, Critical Care, Vaccines (therapeutical & preventive) and diagnostics.

Products
Some available Biogeneric products:

1. Hemapo , for the therapy of anemia in dialysis patients caused by kidney failure
2. Kalferon, for chronic Hepatitis B and C patients
3. Fimalbumin, for hypoproteinemia management, with or without edema
4. Fimakinase, for acute miokard infarct therapy, vena cava inferior thrombosis, acute massive lung embolism , acute thrombosis and artery embolism
5. BTXA , for the therapy of strabismus and blepharospasm caused by dystonia
6. Mediflex, a break-through formula to ease topical transdermal arthritis pain
7. Leucogen, a product to ease fever, which is still in evaluation process for patients with non-myeloid under chemotherapy.

BAHASA INDONESIA